Panelists discuss how patients experiencing frequent anti-VEGF treatment burdens with 4- to 8-week intervals between injections are ideal candidates for PDS as an alternative delivery method.

The 1-year results from the HELIOS Trial that evaluated the investigational intravitreal Axitinib implant (OTX-TKI, Ocular Therapeutix) for the treatment of non-proliferative diabetic retinopathy ...

Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard ...

Hello and welcome to this video series sponsored by Bayer in which we are going to explore Eylea 8 mg for the treatment of age-related macular degeneration and diabetic macular edema. I am Professor ...

A European study found that temperature changes have the potential to adversely affect anti-vascular endothelial growth factor (VEGF) drugs when patients store them in their homes. These changes can ...

They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA ...

Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides ...

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their ...

Panelists discuss how surgeons must complete specialized training and certification through the risk evaluation and mitigation strategy program to perform port delivery system implantation, which ...